Infinity Pharma (INFI) – Press Releases
-
INFINITY ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Infinity Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Applied Digital, Infinity, and Shift4 and Encourages Investors to Contact the Firm
-
ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – INF
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Live Nation, Applied Digital, and Infinity and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Infinity, Shift4, and Comerica and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Infinity, Shift4, and Comerica and Encourages Investors to Contact the Firm
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INFI
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INFI
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bausch, Applied Digital, and Infinity and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Infinity, HUB, and Shift4 and Encourages Investors to Contact the Firm
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INFI
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Applied Digital, Infinity, and HUB and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Infinity, HUB, and Shift4 and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Applied Digital and Infinity and Encourages Investors to Contact the Firm
-
Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan
-
Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma
-
MEI Pharma Reminds Shareholders to Vote Today FOR the Infinity Transaction
-
MEI Pharma Encourages Shareholders to Vote FOR the Infinity Transaction
-
Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma
-
MEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity Pharmaceuticals
-
Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with S
-
MEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity Pharmaceuticals
-
ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.
-
MEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote “FOR” Pending Transaction with Infinity Pharmaceuticals
-
MEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals
-
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
-
MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
-
Infinity Pharmaceuticals Announces Two Upcoming Presentations on PI3K-γ and Eganelisib by Dr. Judith Varner at the 2023 Annual Meeting of the American Association of Cancer Research
-
Infinity Pharmaceuticals Reports Full Year 2022 Financial Results
-
MEI Pharma and Infinity Pharmaceuticals Announce Definitive Merger Agreement to Advance Three Promising Clinical Oncology Candidates
-
Infinity Pharmaceuticals to Participate in Piper Sandler 34th Annual Healthcare Conference
-
Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
-
Infinity Pharmaceuticals Provides MARIO-3 Update in Patients with Front Line Metastatic Triple Negative Breast Cancer Suggesting Potential Long-Term Patient Benefit of Eganelisib
-
Infinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast
-
Infinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences
-
Infinity Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
-
Infinity Pharmaceuticals Announces the Date of Its Second Quarter 2022 Financial Results Conference Call and Webcast
-
Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference
-
Infinity Pharmaceuticals Reports First Quarter 2022 Financial Results
-
Infinity Pharmaceuticals Announces the Date of Its First Quarter 2022 Financial Results Conference Call and Webcast
-
Infinity Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Infinity Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Company Highlights
-
Infinity Pharmaceuticals Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast
-
Infinity Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference
-
Infinity Pharmaceuticals to Be Featured in a Fireside Chat as Part of B. Riley’s 2022 Virtual Oncology Conference
-
Infinity to Present at 40th Annual J.P. Morgan Healthcare Conference
-
Infinity Pharmaceuticals Outlines Eganelisib Clinical Development Strategy and Provides 2022 Guidance
-
Infinity Pharmaceuticals Added to the NASDAQ Biotechnology Index
-
Infinity Pharmaceuticals to be Featured in B. Riley Fireside Chat
-
Encouraging Updated Data from Phase 2 MARIO-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium
Back to INFI Stock Lookup
